Viewing Study NCT06504394

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2026-03-10 @ 11:51 PM
Study NCT ID: NCT06504394
Status: RECRUITING
Last Update Posted: 2025-12-01
First Post: 2024-07-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Classical Hodgkin Lymphoma Recurrent View
None Classical Hodgkin Lymphoma Refractory View
None Primary Mediastinal Large B-cell Lymphoma Recurrent View
None Primary Mediastinal Large B-cell Lymphoma Refractory View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None Programmed Death-Ligand 1 (PDL1, PD-L1) View
None Programmed Cell Death-2 (PD2, PD-2) View
None Programmed Death-Ligand 2 (PDL2, PD-L2) View